Debiopharm
↗Lausanne, Switzerland
Debiopharm is an independent Swiss biopharmaceutical company committed to developing innovative therapies to improve patient outcomes and quality of life, primarily in oncology and bacterial infections. The company operates through a distinctive business model of in-licensing promising drug candidates from universities and smaller biotechs, adding value through clinical development, regulatory navigation, and strategic partnerships. With operations in Lausanne (drug development and digital health investment) and Martigny (manufacturing), Debiopharm has established itself as a notable player in ADC (antibody-drug conjugate) technology and specialized oncology therapeutics.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology biotech, Antibody-drug conjugates, Infectious disease therapeutics
SIZE & FINANCIALS
Employees:251-500
Founded:1979
Ownership:private
Status:operating
FUNDING
Stage:Private
Investors:Après-demain SA (parent company)
PIPELINE
Stage:Phase 1, Phase 2, Phase 3
Lead Drug Stage:Phase 3 (Debio 4126 - octreotide for acromegaly)
Modalities:Antibody-Drug Conjugates (ADCs), Small molecule kinase inhibitors, Peptides, Antibodies, Antibiotics
Active Trials:4
Trial Phases:Phase 1: 2 | Phase 2: 2 | Phase 3: 1
FDA Approvals:2
EMA Approvals:2
CORPORATE STRUCTURE
Parent Company:Après-demain SA
Subsidiaries:Debiopharm International SA, Debiopharm Research & Manufacturing SA, Debiopharm Innovation Fund
Key Partnerships:GARDP (Global Antibiotic Research & Development Partnership) - Jan 2026 for Debio 1453 gonorrhea treatment, Repare Therapeutics - July 2025 for lunresertib worldwide licensing, Genome & Company (South Korea) - May 2024 for ADC development using Multilink™, NetTargets (South Korea) - Oct 2025 AI collaboration for dual-payload ADCs, WhiteLab Genomics - Sept 2024 for AI-driven drug target design, Aurigene Discovery Technologies Ltd - 2008 for Debio 0617 (kinase inhibitor), MEDSIR - Clinical collaboration for Debio 0123 in breast cancer, Ipsen - Commercial partnership for triptorelin (Decapeptyl), Sanofi - Commercial partnership for oxaliplatin (Eloxatin)
COMPETITION
Position:Challenger/Niche Player - Strong in ADC technology and DDR inhibitors
Competitors:Eli Lilly (oncology), Johnson & Johnson (oncology), Amgen (oncology/biosimilars), Sandoz (biosimilars), Samsung Bioepis (biosimilars), Mabxience (biosimilars), Other oncology biotech companies in ADC space
LEADERSHIP
Key Executives:
Dr. Ducrey - Chief Executive Officer
Thierry Mauvernay - President
Vanessa Currat - Chief Legal Officer
Dr. Lévy - Chief Scientific Officer, Search & Evaluation and Scientific Innovation
Valérie Calvayrac - Senior Vice President, Asset Management
Scientific Founders:Dr. Rolland-Yves Mauvernay (founder 1979, deceased 2017)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Debiopharm and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Debiopharm. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.